Truist Securities Maintains Buy on Neurocrine Biosciences, Lowers Price Target to $140

Neurocrine Biosciences, Inc. +0.63%

Neurocrine Biosciences, Inc.

NBIX

131.63

+0.63%

Truist Securities analyst Danielle Brill maintains Neurocrine Biosciences (NASDAQ: NBIX) with a Buy and lowers the price target from $169 to $140.